Nanocubosomal based in situ gel loaded with natamycin for ocular fungal diseases: development, optimization, in-vitro, and in-vivo assessment

被引:21
|
作者
Hosny, Khaled M. [1 ,2 ]
Rizg, Waleed Y. [1 ,2 ]
Alkhalidi, Hala M. [3 ]
Abualsunun, Walaa A. [1 ]
Bakhaidar, Rana B. [1 ]
Almehmady, Alshaimaa M. [1 ]
Alghaith, Adel F. [4 ]
Alshehri, Sultan [4 ]
El Sisi, Amani M. [5 ]
机构
[1] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah 21441, Saudi Arabia
[2] King Abdulaziz Univ, Ctr Excellence Drug Res & Pharmaceut Ind, Jeddah, Saudi Arabia
[3] King Abdulaziz Univ, Fac Pharm, Dept Clin Pharm, Jeddah, Saudi Arabia
[4] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh, Saudi Arabia
[5] Beni Suef Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Bani Suwayf, Egypt
关键词
Cubosomes; cornea; in situ gel; keratitis; natamycin; permeation; phytantriol; DRUG-DELIVERY-SYSTEM; OPHTHALMIC DELIVERY; CORNEAL PENETRATION; FORMULATION; CUBOSOMES; INFECTIONS; KERATITIS; NANOPARTICLES; NANOCARRIERS; LIPOSOMES;
D O I
10.1080/10717544.2021.1965675
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Natamycin (NT) is a synthetic broad-spectrum antifungal used in eye drops. However, it has low solubility and high molecular weight, limiting its permeation, and generally causes eye discomfort or irritation when administered. Therefore, the present study aimed to develop an ophthalmic in situ gel formulation with NT-loaded cubosomes to enhance ocular permeation, improve antifungal activity, and prolong the retention time within the eye. The NT-loaded cubosome (NT-Cub) formula was first optimized using an I-optimal design utilizing phytantriol, PolyMulse, and NT as the independent formulation factors and particle size, entrapment efficiency %, and inhibition zone as responses. Phytantriol was found to increase particle size and entrapment efficiency %. Higher levels of PolyMulse slightly increased the inhibition zone whereas a decrease in particle size and EE% was observed. Increasing the NT level initially increased the entrapment efficiency % and inhibition zone. The optimized NT-Cub formulation was converted into an in situ gel system using 1.5% Carbopol 934. The optimum formula showed a pH-sensitive increase in viscosity, favoring prolonged retention in the eye. The in vitro release of NT was found to be 71 +/- 4% in simulated tear fluid. The optimum formulation enhanced the ex vivo permeation of NT by 3.3 times compared to a commercial formulation and 5.2 times compared to the NT suspension. The in vivo ocular irritation test proved that the optimum formulation is less irritating than a commercial formulation of NT. This further implies that the developed formulation produces less ocular irritation and can reduce the required frequency of administration.
引用
收藏
页码:1836 / 1848
页数:13
相关论文
共 50 条
  • [41] Development of ion-triggered in situ gel containing ketoconazole/hydroxypropyl-β-cyclodextrin for ocular delivery: in vitro and in vivo evaluation
    Xia, Huiyun
    Yang, Jingjing
    Song, Fei
    Pu, Guojuan
    Dong, Fudan
    Liang, Zhen
    Zhang, Junjie
    DRUG DELIVERY, 2024, 31 (01)
  • [42] Development of Piperine-Loaded Solid Self-Nanoemulsifying Drug Delivery System: Optimization, In-Vitro, Ex-Vivo, and In-Vivo Evaluation
    Zafar, Ameeduzzafar
    Imam, Syed Sarim
    Alruwaili, Nabil K.
    Alsaidan, Omar Awad
    Elkomy, Mohammed H.
    Ghoneim, Mohammed M.
    Alshehri, Sultan
    Ali, Ahmed Mahmoud Abdelhaleem
    Alharbi, Khalid Saad
    Yasir, Mohd
    Noorulla, Kaveripakkam M.
    Alzarea, Sami I.
    Alanazi, Abdullah S.
    NANOMATERIALS, 2021, 11 (11)
  • [43] Development of Tizanidine HCI-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation
    Zaman, Muhammad
    Hanif, Muhammad
    Shaheryar, Zaib Ali
    PLOS ONE, 2018, 13 (03):
  • [44] Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits
    Fouda, Nagwa Hussein
    Abdelrehim, Randa Tag
    Hegazy, Doaa Abdelmagid
    Habib, Basant Ahmed
    DRUG DELIVERY, 2018, 25 (01) : 1340 - 1349
  • [45] Development of thermosensitive hydrogel of Amphotericin-B and Lactoferrin combination-loaded PLGA-PEG-PEI nanoparticles for potential eradication of ocular fungal infections: In-vitro, ex-vivo and in-vivo studies
    Elhabal, Sammar Fathy
    Ghaffar, Shrouk A.
    Hager, Raghda
    Elzohairy, Nahla A.
    Khalifa, Mohamed Mansour
    Mohie, Passant M.
    Gad, Rania A.
    Omar, Nasreen N.
    Elkomy, Mohammed H.
    Khasawneh, Mohammad Ahmad
    Abdelaal, Nashwa
    INTERNATIONAL JOURNAL OF PHARMACEUTICS-X, 2023, 5
  • [46] Utilization of PEGylated cerosomes for effective topical delivery of fenticonazole nitrate: in-vitro characterization, statistical optimization, and in-vivo assessment
    Albash, Rofida
    Yousry, Carol
    Al-Mahallawi, Abdulaziz Mohsen
    Alaa-Eldin, Ahmed Adel
    DRUG DELIVERY, 2021, 28 (01) : 1 - 9
  • [47] Formulation, Optimization, In-Vitro and In-Vivo Evaluation of Nateglinide-Loaded Nanostructured Lipid Carriers for Enhanced Bioavailability
    Tiwari, Shradha S.
    Dange, Yuvraj D.
    Honmane, Sandip M.
    Saralaya, Mahesh G.
    Gattani, Surendra G.
    Wadher, Shailesh J.
    Sarda, Rohit R.
    Mahaparale, Paresh R.
    BIONANOSCIENCE, 2025, 15 (01)
  • [48] Development and Optimization of Cefuroxime Axetil Nanosuspension for Improved Oral Bioavailability: In-Vitro and In-Vivo Investigations
    Haragouri Mishra
    Amulyaratna Behera
    Sidhartha Sankar Kar
    Swagatika Dash
    Srikanta Moharana
    Suresh Sagadevan
    BioNanoScience, 2023, 13 : 2371 - 2384
  • [49] In-vitro and in-vivo evaluation of chitosan-based thermosensitive gel containing lorazepam NLCs for the treatment of status epilepticus
    Taymouri, Somayeh
    Minaiyan, Mohsen
    Ebrahimi, Farnaz
    Tavakoli, Naser
    IET NANOBIOTECHNOLOGY, 2020, 14 (02) : 148 - 154
  • [50] Development of Gentamicin Bilosomes Laden In Situ Gel for Topical Ocular Delivery: Optimization, In Vitro Characterization, Toxicity, and Anti-microbial Evaluation
    Zafar, Ameeduzzafar
    Alsaidan, Omar Awad
    Mohamed, Malik Suliman
    Yasir, Mohd
    Khalid, Mohammad
    ADVANCED PHARMACEUTICAL BULLETIN, 2024, 14 (03) : 646 - 664